Orforglipron vs LL-37
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronImmune SupportRecovery & Repair
LL-37- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- Admin Route
- Oral
- SubQ, Topical, Intranasal
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 100–300 mcg
- Frequency
- Once daily
- 2–3x per week
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Broad-spectrum antimicrobial (bacteria, fungi, viruses)
- Promotes wound healing and angiogenesis
- Immune system modulation — enhances innate immunity
- Reduces LPS-mediated endotoxemia
- Anti-biofilm activity against resistant organisms
- Promotes tissue regeneration and keratinocyte migration
- May protect against sepsis
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Injection site redness and irritation
- Mild inflammatory response at injection site
- Potential pro-inflammatory at high doses
- Rare: fever or flu-like symptoms at initiation
- Stacks With
- —
- —